Your browser doesn't support javascript.
Guiding axes for drug safety management of pharmacovigilance centres during the COVID-19 era.
Ferreira-da-Silva, Renato; Ribeiro-Vaz, Inês; Morato, Manuela; Polónia, Jorge Junqueira.
  • Ferreira-da-Silva R; Porto Pharmacovigilance Centre, Rua Doutor Plácido da Costa, 4200-450, Porto, Portugal. renato.ivos@gmail.com.
  • Ribeiro-Vaz I; Department of Community Medicine, Health Information and Decision, Porto, Portugal. renato.ivos@gmail.com.
  • Morato M; CINTESIS - Center for Health Technology and Services Research, Porto, Portugal. renato.ivos@gmail.com.
  • Polónia JJ; Porto Pharmacovigilance Centre, Rua Doutor Plácido da Costa, 4200-450, Porto, Portugal.
Int J Clin Pharm ; 43(4): 1133-1138, 2021 Aug.
Article in English | MEDLINE | ID: covidwho-1252181
ABSTRACT
The COVID-19 pandemic presents several challenges to the organisation and workflow of pharmacovigilance centres as a result of the massive increase in reports, the need for quick detection, processing and reporting of safety issues and the management of these within the context of lack of complete information on the disease. Pharmacovigilance centres permanently monitor the safety profile of medicines, ensuring risk management to evaluate the benefit-risk relationship. However, traditional pharmacovigilance approaches of spontaneous reporting, are not suitable in the context of a pandemic; the scientific community and regulators need information on a near real-time point. The aim of this commentary is to suggest six interrelated multidimensional guiding axes for drug safety management by pharmacovigilance centres during the COVID-19 pandemic. This working plan can increase knowledge on COVID-19 and associated therapeutic approaches, support decisions by the regulatory authorities, oppose fake news and promote more efficient public health protection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Adverse Drug Reaction Reporting Systems / Pharmacovigilance / COVID-19 Drug Treatment Type of study: Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Int J Clin Pharm Year: 2021 Document Type: Article Affiliation country: S11096-021-01289-0

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Adverse Drug Reaction Reporting Systems / Pharmacovigilance / COVID-19 Drug Treatment Type of study: Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Int J Clin Pharm Year: 2021 Document Type: Article Affiliation country: S11096-021-01289-0